Market closed · Oct 8, 7:00 am ET · Last extended-hours $13.49 0.00%
Open$13.47
Prev close$13.57
Day range$13.27 – $14.20
Volume1.05M
Market cap$501.07M
P/E (TTM)–
Dividend yield–
CBIO Stock News
Headlines matching Crescent Biopharma or the CBIO ticker, most recent first.
H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Hold RatingMarket news · 31 Jul 2026 · Direct mention
Piper Sandler Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35Market news · 23 Jun 2026 · Direct mention
Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $30Market news · 23 Jun 2026 · Direct mention
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO)TipRanks · 23 Jun 2026 · Direct mention
Wedbush Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $27Market news · 1 Jun 2026 · Direct mention
H.C. Wainwright Downgrades Crescent Biopharma(CBIO.US) to Hold RatingNegativeMarket news · 1 Jun 2026 · Direct mention
H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22Market news · 4 May 2026 · Direct mention
Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $30NegativeMarket news · 1 May 2026 · Direct mention
A Quick Look at Today's Ratings for Crescent Biopharma(CBIO.US), With a Forecast Between $27 to $35Market news · 30 Apr 2026 · Direct mention
H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $22NegativeMarket news · 2 Mar 2026 · Direct mention
LifeSci Capital Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22Market news · 27 Feb 2026 · Direct mention
TD Cowen Maintains Crescent Biopharma(CBIO.US) With Buy RatingMarket news · 27 Feb 2026 · Direct mention
Guggenheim Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35Market news · 27 Feb 2026 · Direct mention
Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $28Market news · 6 Oct 2026 · Direct mention
H.C. Wainwright Upgrades Crescent Biopharma(CBIO.US) to Buy Rating, Announces Target Price $36PositiveMarket news · 6 Oct 2026 · Direct mention
Discussion
No comments yet — be the first to weigh in on CBIO.
No comments yet — be the first to weigh in on CBIO.